Drug
O(6)-benzylguanine clinical trials
Also written O6-benzylguanine.
- studies test it
- 30
- open now
- 1
- in phase 3
- 1
- first study started
- 1996
Keep track of what changes. Save the O(6)-benzylguanine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
29 studies that test it; most in 2000 (6)
| Year | Studies |
|---|---|
| 1996 | 1 |
| 1997 | 1 |
| 1998 | 1 |
| 1999 | 5 |
| 2000 | 6 |
| 2001 | 2 |
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 17
- Phase 2
- 13
- Phase 3
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 29
National Cancer Institute (NCI) (10) · Duke University (6) · Case Comprehensive Cancer Center (4) · Fred Hutchinson Cancer Center (3) · University of Chicago (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · SWOG Cancer Research Network (1) · Leland Metheny (1)
Often tested with
Tested in the same studies.
Carmustine (13) · Temozolomide (10) · P140K (1) · C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs (1) · Filgrastim (1) · Plerixafor (1) · Cytarabine (1) · Melphalan (1)
Studies
Open first, then newest update. How each study uses O(6)-benzylguanine is read from its arms, and is right about nine times in ten.
Testing it · 30
- hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)RecruitingPhase 2Leland MethenyNCT05052957Written as O6-benzylguanine
- O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant GliomasTerminatedPhase 1/2Fred Hutchinson Cancer CenterNCT00669669Written as O6-Benzylguanine
- O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem TumorsCompletedPhase 2National Cancer Institute (NCI)NCT00275002Written as O6-benzylguanine
- HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV InfectionWithdrawnPhase 1Fred Hutchinson Cancer CenterNCT02343666Written as O6-Benzylguanine
- O(6)-Benzylguanine in Treating Patients With Malignant GliomaCompletedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT00002971Written as O6-benzylguanine
- O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell LymphomaCompletedPhase 1/2National Cancer Institute (NCI)NCT00961220Written as O6-Benzylguanine
- O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation TherapyTerminatedPhase 2National Cancer Institute (NCI)NCT00436436Written as O6-benzylguanine
- Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomaWithdrawnNot applicableFred Hutchinson Cancer CenterNCT01769911Written as O6-benzylguanine
- Temozolomide and O6-benzylguanine in Treating Children With Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT00020150Written as O6-benzylguanine
- Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive GliomaCompletedPhase 2Duke UniversityNCT00005081Written as O6-benzylguanine
- Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBMCompletedPhase 1Duke UniversityNCT00612989Written as Temodar and O6-Benzylguanine
- Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant GliomaCompletedPhase 2Duke UniversityNCT00613093Written as Temodar and O6-Benzylguanine (BG)
- O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During SurgeryCompletedPhase 1University of ChicagoNCT00003766Written as O6-benzylguanine
- Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain TumorsCompletedPhase 1National Cancer Institute (NCI)NCT00052780Written as O6-benzylguanine
- O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue SarcomaCompletedPhase 2University of ChicagoNCT00005066Written as O6-benzylguanine
- Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic GliomaCompletedPhase 1Duke UniversityNCT00006474Written as O6-benzylguanine
- Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma MultiformeWithdrawnPhase 2Duke UniversityNCT00046878Written as O6-benzylguanine
- Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the BrainCompletedPhase 1Duke UniversityNCT00003348Written as O6-benzylguanine
- O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT00005961Written as O6-benzylguanine
- O6-benzylguanine and Carmustine in Treating Children With Refractory CNS TumorsCompletedPhase 1National Cancer Institute (NCI)NCT00003765Written as O6-benzylguanine
See all 30 studies that test O(6)-benzylguanine →
Given in every arm · 1 — O(6)-benzylguanine is usual care beside what is tested
Codes
What other systems call O(6)-benzylguanine · ClinicalTrials.gg INT003523
- MeSH (NLM) C064976O(6)-benzylguanineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 01KC87F8FE6-O-BENZYLGUANINEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C064976 | O(6)-benzylguanine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 01KC87F8FE | 6-O-BENZYLGUANINE | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.